I agree.. Anyone that makes a living profiting from the deaths of others is pathetic
Notice the correlation of his articles and timing just after run ups in stocks.
This so called man has an agenda...
It's hilarious that he questions an analysts motives when his are so obviously tainted.
Sentiment: Strong Buy
Adam Fraudstein's track record of being wrong is perfect.
He is wrong every time, and continues his flawless losing record.
First they said Afrezza would never get past Adcomm..
Fraudstein was wrong.. Passed with flying colors.
Next they said it would never be approved by FDA.
He was wrong yet again.
Now he says when 20 doctors were interviewed about Afrezza,
ONE said they wouldn't prescribe it... Seriously... ONE...
According to him, that's negative...
TALK ABOUT HAVING AN AGENDA FRAUDSTEIN.
You and your employer (TheStreet, IE Jim Cramer) have been paid bashers since day one.
Your attempts to bash a life saving drug are just a pathetic attempt to make money at others welfare.
It amazes me that people still listen to his broken record.
This will keep production cost down and since marketing and distribution are taken care of by Sonofi will make profits much easier to come by in the future.
And as I mentioned many times during the approval process, Afrezza is just the tip of the iceberg.
It's the Technosphere Technology that is going to take the stock to the next level.
Taking pills by mouth or injections may become a thing of the past when you can turn a drug into a inhalable powder that will react much faster in your body.
Preliminary data for Neuvax is scheduled to release by the Q4 2015 - Q1 2016.
Q3 starts in 3 weeks... That means not only do we have a second drug approved by the FDA being released next month, we will also get updates on Neuvax in 3-6 months.
The two drugs they will have out will help on slowing burn rate, but Neuvax is the real game changer for Breast, Ovarian, and Endometrial Cancers....if Neuvax continues to work as well as it did in P2, and gets approved there is no doubt it will be a blockbuster.
Abstral is already out, Ziplenz is set to be launched in. July...so they will have two drugs on market.
Now I know they won't be showing huge sales immediately, but as they show sequential revenue growth, people will get excited. As revenues grow, losses will shrink.
The beauty is by the time Neuvax launches revenues will be substantially higher, which opens door to quicker march to profits.
It also makes GALE a more attractive take out or partnership target. Any money brought in by partnerships will have that much more value as the burn rate shrinks.
Thanks.. I appreciate your kind words.. I agree that life saving drugs that are effective and well-tolerated should get a faster track to approval. That being said, on the stock side, i don't think we will have to wait until approval to see this company move up. Investors will want to be in way before we are anywhere near application time. If preliminary phase 3 results come in anywhere near the phase 2 results, you will see hordes of investors jumping in.
With second drug coming out in July, and revenues gaining traction quarter after quarter, I think everything points towards up for share value.
I hate to be one of these pie in the sky "maybe there'll be a take over" people, but if there was ever a company that I owned shares in that would be prime for takeover I think GALE would be a prime target.
At the very least, we should see a rich distribution partnership formed in the not-too-distant future.
Jim Kramer is a notorious short when it comes to small biotechs. He, his website TheStreet, and his monkey boy Adam Fraudstein, will bash.. But at some point it loses it's effectiveness... It bothers me because the because shorting a company that is working on saving lives lessens it's value, making it harder to raise capital to fund it's ongoing research..
It shows a complete disregard for human life... Hope he sleeps well at night.
GALE Will have two approved drugs on the market, revenues will continue to grow, as we wait for preliminary phase 3 results for the drug that will put us over the top. Neuvax will be the closest thing to a cure for certain types of breast cancer on the market, if approved. Chances of reoccurrence will drop from almost 25% to only 5%.
If someone told you that there is a 1 in. 4 chance your cancer would return, but told you that by taking this drug your chances would drop to 1 in 20, any logical person would jump at the chance of taking this drug.
Doctors will be quick to prescribe, and insurance companies will be glad to cover.
To say the potential of this drug is huge would be a major understatement.
My mother had breast cancer which went 10 years without coming back but when it did, it metastasized and spread throughout her whole body causing her to die at age 58 when I was only 19. I can only hope that this drug is approved and save thousands of lives so that people don't have to die like my mother did.
Looking strong and definitely trending up.
I would say that is a very attainable target. Once we hold above $2.40, next resistance is small in low $2.60s, the easy run to $3.00+.. Once low 3s are washed out flood gates wide open to run.
Didn't think we would hit short term goal in a day, but I am liking it.
We broke through key resistance and then some,
As you can see from today's PR, huge news coming in very short term.
Anticipation rally not far out...
Been through this with two other companies recently.
Huge binary events on near term horizon.
Regardless of results, which for all intensive purposes should be positive, we will rally just on anticipation.
Anything positive could send this stock running 100-200% in a blink.
Small float and relatively thinly traded..
My guess is we push $2.40 near term...
A break above could send us running.
Minor correction: preliminary result by end of year - final results in '16..
Anticipation for results will send us running
Sentiment: Strong Buy
Hi Koch...yes P3= Phase 3 trials.. IE final trials before a drug candidate puts in for its NDA (new drug application) with the FDA for approval. Sometime this year Synta Will give its phase three results. Soon after it will file with the FDA. At this time the market cap will better reflect the potential for the drug if that is approved. A large part of the time the market Will be anywhere from a
500m-1B for a small company such as Synta. I have seen several other companies in a similar position have market caps of 2 billion or more. Playing conservative Synta should be priced nearly 50% more than it currently is. And a market analyst even have a $7 12 month price target.
I will be amazed if the stock doesn't hit $4 before the end of the year. Considering that's almost double from where we are now, I would say it's well worth a seven-month wait and see.
This is just my opinion based on 3 decades of trading... That's my $.02
Sentiment: Strong Buy
You know all those rich folk that got warrants priced at $2.08 weren't throwing away their money.
My estimate is we will bust it easily! more like $3+ when they announce first look at Phase 3 early data
Sentiment: Strong Buy